Table 1. Characteristics of patient groups.
| AD MB− | AD MB+ | P | |
|---|---|---|---|
| N | 12 | 6 | |
| Male/female (% male) | 7/5 (58%) | 6/0 (100%) | 0.07 |
| Age (years) | 63±8 | 66±2 | 0.12 |
| MMSE | 23±3 | 23±3 | 0.81 |
| Injected dose (MBq) | 348±30 | 324±48 | 0.35 |
| Specific activity (GBq/μmol) | 60±36 | 51±34 | 0.45 |
AD MB−, Alzheimer's disease patient group without microbleeds; AD MB+, Alzheimer's disease patient group with microbleeds; MMSE, mini-mental state examination; injected dose, injected dose of (R)-[11C]verapamil; specific activity, specific activity of (R)-[11C]verapamil.
Group differences were calculated using Mann–Whitney U tests.